AR008765A1 - Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del - Google Patents

Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del

Info

Publication number
AR008765A1
AR008765A1 ARP970102432A ARP970102432A AR008765A1 AR 008765 A1 AR008765 A1 AR 008765A1 AR P970102432 A ARP970102432 A AR P970102432A AR P970102432 A ARP970102432 A AR P970102432A AR 008765 A1 AR008765 A1 AR 008765A1
Authority
AR
Argentina
Prior art keywords
composite
same
peptide
recombinant
derivative
Prior art date
Application number
ARP970102432A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR008765A1 publication Critical patent/AR008765A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP970102432A 1996-06-06 1997-06-04 Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del AR008765A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds

Publications (1)

Publication Number Publication Date
AR008765A1 true AR008765A1 (es) 2000-02-23

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102432A AR008765A1 (es) 1996-06-06 1997-06-04 Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del

Country Status (15)

Country Link
EP (1) EP0912609A2 (no)
JP (1) JP2000512137A (no)
KR (1) KR20000016402A (no)
CN (1) CN1221426A (no)
AR (1) AR008765A1 (no)
AU (1) AU3337297A (no)
BR (1) BR9709529A (no)
CA (1) CA2257240A1 (no)
CZ (1) CZ397898A3 (no)
IL (1) IL127153A0 (no)
NO (1) NO985683L (no)
NZ (1) NZ332879A (no)
PL (1) PL330361A1 (no)
TR (1) TR199802534T2 (no)
WO (1) WO1997046585A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007014A2 (en) 1998-07-28 2000-02-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) * 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2388417A1 (en) 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
CA2407872C (en) 2000-05-22 2013-11-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Receptor-based interaction trap
WO2003034996A2 (en) 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
ES2300817T3 (es) 2003-09-08 2008-06-16 Laboratoires Serono Sa Tratamiento de enfermedades fibroticas.
CN103897066A (zh) 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
US20110059969A1 (en) 2007-12-05 2011-03-10 Astrazeneca Ab Piperazines as anti-obesity agents
WO2009071668A2 (en) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Piperazine derivatives and their use as leptin receptor modulators
BRPI0913448A2 (pt) * 2008-06-04 2015-12-01 Astrazeneca Ab composto, formulação farmacêutica, uso de um composto, e, método para o tratamento ou prevenção das condições ou doenças que são prevenidas, tratadas, ou melhoradas pela ação seletiva por intermédio do receptor de leptina0.
MX2010013355A (es) * 2008-06-04 2010-12-21 Astrazeneca Ab Nuevos compuestos v.
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
ES2602436T3 (es) * 2010-05-11 2017-02-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Inhibidor basado en péptido de la activación de interleucina 10 o STAT-3
EA032917B1 (ru) 2010-09-28 2019-08-30 Амилин Фармасьютикалс, Ллк Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU4766096A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CN1221426A (zh) 1999-06-30
JP2000512137A (ja) 2000-09-19
AU3337297A (en) 1998-01-05
WO1997046585A2 (en) 1997-12-11
KR20000016402A (ko) 2000-03-25
EP0912609A2 (en) 1999-05-06
WO1997046585A3 (en) 1998-04-23
CA2257240A1 (en) 1997-12-11
BR9709529A (pt) 1999-08-10
NO985683D0 (no) 1998-12-04
IL127153A0 (en) 1999-09-22
TR199802534T2 (xx) 1999-03-22
NO985683L (no) 1998-12-04
PL330361A1 (en) 1999-05-10
CZ397898A3 (cs) 1999-04-14
NZ332879A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
ATE556719T1 (de) Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
CO4790174A1 (es) Analogos del peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
RS51602B (sr) April receptor (bcma) i njegova upotreba
ES2187756T3 (es) Uso de una composicion farmaceutica que comprende un peptido supresor del apetito.
ES2052729T3 (es) Un procedimiento para aplicar un revestimiento compuesto a un sustrato.
AR002024A1 (es) Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
AU1633200A (en) Human parathyroid hormone modifications, preparation and use
BR9807618A (pt) Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa.
AR008094A1 (es) Proceso para la sintesis de un polipeptido sintetico analogo a la hormona paratiroidea o al peptido relacionado con la hormona paratiroidea y procesopara la preparacion de una composicion farmaceutica.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
AR024742A1 (es) DERIVADOS CICLOPEPTIDICOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFA v BETA 6, LOS MEDICAMENTOS A BASE DE ESTOS COMPUESTOS, LAS COMPOSICIONESFARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS MEDICAMENTOS, Y EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO.
DE69837997D1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
DK527187D0 (da) Gonadoliberin-analoge, fremgangsmaade til deres fremstilling samt deres anvendelse som laegemidler
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
EP0717752A4 (en) THERAPEUTIC COMPOUNDS
FI942392A0 (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
ES2160594T3 (es) Antigenos protectores contra la infeccion por echinococcus granulosus y vacunas que contienen estos antigenos.
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines

Legal Events

Date Code Title Description
FB Suspension of granting procedure